GlaxoSmithKline shares have performed well off the back of the defensive attractions of its sector and improved sentiment around the stock after separating from its consumer health business. However, a lack of balance sheet flexibility and a pipeline of dependent variables means challenges await the drug giant.
To continue reading this article...
Join Investment Week for free
Signup and gain exclusive members-only insights - all free of charge!
- Unlimited access to real-time news, analysis and opinion from the investment industry, including the Sustainable Hub covering fund news from the ESG space
- Get ahead of regulatory and technological changes affecting fund management
- Important and breaking news stories selected by the editors delivered straight to your inbox each day
- Weekly members-only newsletter with exclusive opinion pieces from leading industry experts
- Be the first to hear about our extensive events schedule and awards programmes
